Evaluation of CA19-9 as a tumor marker in urothelial malignancy

References

• Pisani P. Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55: 891–903.
   Google Scholar
• Cancer Registry Annual Report, Department of Health, Taiwan, Republic of China. Taipei: Executive Yuan, 2000.
   Google Scholar
• Raghavan D, Shipley WU, Gamick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med 1990; 322: 1129–38.
   PubMed Web of Science ®Google Scholar
• Newling DW. Preventing recurrence and progression in superficial bladder cancer. Curr Opin Urol 1996; 6: 272–9.
   Google Scholar
• Pirtskalaishvili G, Konety BR, Getzenberg RH. Update on urine-based markers for bladder cancer. How sensi-tive and specific are the new non-invasive tests? Postgrad Med 1999; 106: 85–94.
   Google Scholar
• Grossman HB. New methods for detection of bladder cancer. Semin Urol Oncol 1998; 16: 17–22.
   PubMedGoogle Scholar
• Shelfo SW, Soloway MS. The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder. World J Urol 1997; 15: 107–11.
   PubMed Web of Science ®Google Scholar
• Papanicolaou GN, Marshall VF. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 1945; 101: 519–20.
   PubMed Web of Science ®Google Scholar
• Brown FM. Urine cytology. Is it still the gold standard for screening? Urol Clin N Am 2000; 27: 25–37.
   Google Scholar
• Gregoire M, Fradet Y, Meyer F, Tetu B, Bois R, Bedard G, et al. Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors. J Urol 1997; 157: 1660–4.
   PubMed Web of Science ®Google Scholar
• Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999; 161: 388–94.
   PubMed Web of Science ®Google Scholar
• Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigen detected by hybridoma antibodies. Somat Cell Mol Genet 1979; 5: 957–72.
   Google Scholar
• Benini L, Cavallini G, Zordan D, Rizzotti P. Rigo L, Brocco G, et al. A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5 and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas 1988; 3: 61–6.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Kovatich A. HBME-1, a monoclonal antibody useful in the differential diagnosis of mesothe-lioma, adenocarcinoma, and soft-tissue and bone tumors. Appl Immunohistochem 1995; 3: 115–22.
   Google Scholar
• Sugaya Y, Ochi M, Hashimoto S, Muraki J, Morita T, Kobayashi Y, et al. A case of transitional cell carcinoma of renal pelvis with extremely high serum levels of CA19-9 and CEA. Acta Urol Jpn 1997; 43: 495–9.
   PubMedGoogle Scholar
• Segawa N, Yamamoto K, Watsuji T, Suzuki T, Ueda H, Katsuoka Y. Ureteral cancer producing carbohydrate antigen 19-9: report of a case. Acta Urol Jpn 1997; 43: 665–8.
   PubMedGoogle Scholar
• Casetta G, Piana P. Cavallini A, Vottero M, Tizzani A. Urinary levels oftumor-associated antigens (CA19-9, TPA and CEA) in patients with neoplastic and non-neoplastic urothelial abnormalities. Br J Urol 1993; 72: 60–4.
   Google Scholar
• Noto K, Fujime M, Isobe H, Wakumato Y, Kawachi Y. Determination of urinary CA19-9 levels in urothelial cancer-assessment of its role in diagnosis. Jpn J Urol 1997; 88: 406–13.
   Google Scholar
• Lin C-W, Lin JC, Prout GR Jr. Establishment and characterization of four human bladder tumor cell lines and sublines with different degrees of malignancy. Cancer Res 1985; 45: 5070–9.
   Google Scholar
• Bubenik J, Baresova M, Viklicky V. Jakoubkova J, Sainerova H, Donner J. Established cell line of urinary bladder carcinoma (T-24) containing tumor-specific antigen. Int J Cancer 1973; 11: 765–73.
   Google Scholar
• McGovern F, Kachel T, Vijan S, Schiff S, Lin CW, Prout GR Jr. Establishment and characterization of a doxorubicin-resistant human bladder cancer cell line (MGH-U1R). J Urol 1988; 140: 410–4.
   Google Scholar
• Yeh MY, Yu DS, Chen SC, Lin MS, Chang SY, Ma CP, et al. Establishment and characterization of a human urinary bladder carcinoma cell line (TSGH-8301). J Surg Oncol 1988; 37: 177–84.
   PubMed Web of Science ®Google Scholar
• Chuang C-K, Liao S-K. Differential expression of CD44 variant isoforms by cell lines and tissue specimens of transitional cell carcinomas. Anticancer Res 2003; 23: 4635–40.
   Google Scholar
• Otto T, Goepel M, Heider KH, Rubben H. Prognostic factors for bladder cancer. Urol Res 1995; 23: 137–41.
   PubMedGoogle Scholar
• Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002; 167: 80–3.
   Google Scholar
• Oge 0, Atsu N, Sahin A, Ozen H. Comparison of BTA stat and NMP22 tests in the detection of bladder cancer. Scand J Urol Nephrol 2000; 34: 349–51.
   Google Scholar
• Boukamp P. Rupniak HT, Fusenig NE. Environmental modulation of the expression of differentiation and malignancy in six human squamous cell carcinoma cell lines. Cancer Res 1985; 45: 5582–92.
   Google Scholar
• Chuang C-K, Shen Y-C, Wu J-H, Tsai L-H, Liao S-K. Immunobiologic, cytogenetic and drug response features of a newly established cell line (SCRC-1) from renal small cell carcinoma. J Urol 2000; 163: 1016�21.
   Google Scholar
• Yu DS, Chang SY, Ma CP. The correlation of membranous glycoprotein-gp-170, cytoplasmic glutathione and glucose-6-phosphate dehydrogenase levels with multidrug resistance in transitional cell carcinoma cell lines of the urinary tract. J Urol 1997; 157: 727�31.
   Google Scholar
• Fidler IJ. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev 1986; 5: 29�49.
   Web of Science ®Google Scholar
• Langkilde NC, Hastrup J, Olsen S, Wolf H, Orntoft TF. Immunohistochemistry and cytochemistry of experimental rat bladder cancer: binding of the lectins PNA and WGA and of a Le(Y) mouse monoclonal antibody. J Urol 1989; 141: 981�6.
   Google Scholar
• Inai H, Shimazui T, Yamamoto T, Yamauchi A, Uchida K, Takeshima H, et al. A case of transitional cell carcinoma of the urinary bladder with high serum level of CEA and CA19-9. Acta Urol Jpn 2001; 47: 583�6.
   Google Scholar
• Pectasides D, Bafaloucos D, Antoniou F, Gogou L, Economides N, Varthalitis J, et al. TPA, TATI, CEA, A-HCG, PSA, SCC, and CA19-9 for monitoring transitional cell carcinoma of the bladder. Am J Clin Oncol 1996; 19: 271�7.
   Web of Science ®Google Scholar
• Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA19-9 HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer Cytopathol 1998; 84: 101�8.
   Google Scholar
• Vestergaard EM, Wolf H, Orntoft TF. Increased concentrations of genotype-interpreted CA19-9 in urine of bladder cancer patients mark diffuse atypia of the urothelium. Cancer Chem 1998; 44: 197�204.
   Google Scholar
• Pittiglio DH. Genetic and biochemistry of A, B, H and Lewis Antigens. In: Wallace ME, Gibbs FL, editors. Blood Group System: ABH and Lewis, Arlington, Virginia: American Association of Blood Bank; 1986. p. 31�5.
   Google Scholar
• Lin M, Shieh SH. Postnatal development of red cell Le(a) and Le(b) antigens in Chinese infants. Vox Sanguinis 1994; 66: 137�40.
   Web of Science ®Google Scholar
• Lin M. Blood groups and transfusion medicine in Taiwan. J Formos Med Assoc 1997; 96: 933�42.
   Web of Science ®Google Scholar
• Langkilde NC, Wolf H, Meldgard P, Orntoft TF. Frequency and mechanism of Lewis antigen expression in human urinary bladder and colon carcinoma patients. Br J Cancer 1991; 63: 583�6.
   Web of Science ®Google Scholar